Roche Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living with Overweight and Obesity
The choice between medications should rest primarily on efficacy data, tolerability, availability, and cost rather than the B12 inclusion, which is valuable in both formulations
Communicate with Compounding Partners : Contact current 503A and 503B suppliers to confirm their plans and ensure supply until the respective deadlines
Across the SURPASS trials documented in the Mounjaro FDA prescribing information, injection-site reactions occurred in approximately 3-7% of participants depending on dose, while true systemic allergic responses (hives spreading beyond the site, facial swelling, breathing difficulty) are rare
Patients with certain genetic profiles respond better to semaglutide, while others achieve superior outcomes with tirzepatide or dual-compound approaches like GLP-Squared